The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Predicting survival outcomes in colorectal cancer with the STING pathway
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses the potential role of the STING pathway as a predictor of treatment outcomes in patients with colorectal cancer. The pathway is involved in interferon activation and analysis of data from two trials suggested the predicative nature of the STING pathway. Prof. Lenz additionally highlights a new generation of STING agonists under developments that are synergistic with immune checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
